Enanta Historical Income Statement
| ENTA Stock | USD 8.56 0.45 4.99% |
Historical analysis of Enanta Pharmaceuticals income statement accounts such as Selling General Administrative of 63.9 M or Total Revenue of 104.9 M can show how well Enanta Pharmaceuticals performed in making a profits. Evaluating Enanta Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Enanta Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Enanta Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enanta Pharmaceuticals is a good buy for the upcoming year.
Enanta |
About Enanta Income Statement Analysis
Enanta Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Enanta Pharmaceuticals shareholders. The income statement also shows Enanta investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Enanta Pharmaceuticals Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Enanta Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Enanta Pharmaceuticals minus its cost of goods sold. It is profit before Enanta Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Enanta Pharmaceuticals. It is also known as Enanta Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Enanta Pharmaceuticals income statement and is an important metric when analyzing Enanta Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from Enanta Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Enanta Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.At present, Enanta Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 104.9 M, whereas Depreciation And Amortization is forecasted to decline to about 1.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 83.2M | 79.2M | 91.1M | 104.6M | Total Revenue | 86.2M | 79.2M | 91.1M | 104.9M |
Enanta Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Enanta Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enanta Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 3.6M | 3.3M | 3.0M | 2.4M | 2.7M | 1.9M | |
| Interest Expense | 10.3M | 5.3M | 1.6M | 5.1M | 5.9M | 3.1M | |
| Selling General Administrative | 27.4M | 32.5M | 45.5M | 52.9M | 60.8M | 63.9M | |
| Total Revenue | 122.5M | 97.1M | 86.2M | 79.2M | 91.1M | 104.9M | |
| Gross Profit | 122.5M | 97.1M | 83.2M | 79.2M | 91.1M | 104.6M | |
| Other Operating Expenses | 164.1M | 206.6M | 210.0M | 216.4M | 248.9M | 261.3M | |
| Operating Income | (41.6M) | (109.6M) | (123.8M) | (137.2M) | (123.5M) | (117.3M) | |
| Ebit | (41.6M) | (109.6M) | (122.2M) | (125.8M) | (113.3M) | (107.6M) | |
| Research Development | 136.8M | 174.1M | 164.5M | 163.5M | 188.1M | 197.5M | |
| Ebitda | (38.0M) | (106.2M) | (119.2M) | (123.5M) | (111.1M) | (105.6M) | |
| Total Operating Expenses | 164.1M | 206.6M | 210.0M | 216.4M | 248.9M | 261.3M | |
| Income Before Tax | (35.0M) | (107.6M) | (122.2M) | (131.0M) | (117.9M) | (112.0M) | |
| Total Other Income Expense Net | 6.6M | 2.0M | 1.7M | 6.2M | 7.1M | 7.5M | |
| Net Income | (36.2M) | (79.0M) | (121.8M) | (133.8M) | (120.4M) | (114.4M) | |
| Income Tax Expense | 1.1M | (28.6M) | (433K) | 2.8M | 2.5M | 3.0M | |
| Net Income Applicable To Common Shares | 46.4M | (36.2M) | (79.0M) | (121.8M) | (109.6M) | (104.1M) | |
| Net Income From Continuing Ops | (36.2M) | (79.0M) | (121.8M) | (133.8M) | (120.4M) | (114.4M) | |
| Tax Provision | 1.1M | (28.6M) | (433K) | 2.8M | 2.5M | 2.4M | |
| Interest Income | 6.5M | 2.0M | 1.6M | 11.4M | 13.1M | 13.7M | |
| Net Interest Income | 6.5M | 2.0M | 1.6M | 6.2M | 7.1M | 4.7M | |
| Reconciled Depreciation | 3.6M | 3.3M | 3.0M | 2.4M | 2.7M | 3.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (5.45) | Revenue Per Share 3.407 | Quarterly Revenue Growth (0.05) | Return On Assets (0.17) |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.